Name: Latest research reports of Hindustan Petroleum Corporation Ltd. authored by Emkay and published by - Trendlyne research reports.
Item: Hindustan Petroleum Corporation Ltd.
Rating: 5
Author: Emkay

Summary	Date	Stock	Author	LTP	Target	Price at reco (Change since reco%)	Upside(%)	Type	Report	Discuss
	24 Jan 2025	Hindustan Petroleum	Emkay Target	434.40	450.00	352.85 (23.11%)	Target met	Buy	pdf post cache	Broker Report Better refining drives profitability beat; outlook steady Emkay HPCL reported better than expected Q3FY25 earnings with EBITDA/PAT of Rs64.5/30.2bn, a 10%/19% beat, driven by better-than-expected GRMs and marketing volumes. pdf Copy Link Share on Share on Share on Share on Alert
	24 Jan 2025	Godrej Consumer Products	Emkay Reco Target	1148.60	1100.00	1130.35 (1.61%)	Target met	Sell	pdf post cache	Broker Report Near-term outlook weak; step up in execution is key Emkay GCPL has been a play on execution for a couple of years now. Our downgrade (to Reduce) after the Q3 business update factored in concerns on slowdown in/waning of execution. pdf Copy Link Share on Share on Share on Share on Alert
	24 Jan 2025	Ujjivan Small Finance	Emkay	48.23	45.00	33.05 (45.93%)	Target met	Buy	pdf post cache	Broker Report Manages headline NPAs with an eye on Universal bank license Emkay Ujjivan SFB logged a 30% miss on PAT at Rs1.1bn, mainly due to sharp contraction in margin and higher provisions as NPAs surged in the MFI portfolio driven by imposition of MFIN guardrails. pdf Copy Link Share on Share on Share on Share on Alert
	24 Jan 2025	Dr. Reddy's Labs	Emkay Target	1244.70	1150.00	1224.40 (1.66%)	Target met	Sell	pdf post cache	Broker Report Core US business weakness coming to the fore Emkay Adjusted for the milestone payment received from Journey Medical Corp, 3QFY25 EBITDA for Dr Reddy’s was below street/our estimates. The PAT miss was higher on account of lower other income. pdf Copy Link Share on Share on Share on Share on Alert
	24 Jan 2025	Coforge	Emkay Target	1600.80	8600.00	9234.60 (-82.67%)	Target met	Sell	pdf post cache	Broker Report Stellar revenue growth; another quarter of profit miss Emkay Coforge reported strong topline growth of 8.4% QoQ (CC), well ahead of our estimate of 4.7%. Growth was healthy across most horizontals, verticals, and geographies. pdf Copy Link Share on Share on Share on Share on Alert
	23 Jan 2025	Cyient	Emkay Reco Target	1149.40	1700.00	1755.30 (-34.52%)	Target met	Sell	pdf post cache	Broker Report Another quarter of operating performance miss; downgrade to REDUCE Emkay Cyient posted inline revenue performance in DET in Q3, while EBITM missed estimates. DET revenue grew 1.3% QoQ (2.4% CC) to USD175.2mn. DET EBITM declined by 70bps QoQ to 13.5%, coming in below our estimate. pdf Copy Link Share on Share on Share on Share on Alert
	23 Jan 2025	Zee Entertainment	Emkay Target	114.21	130.00	120.75 (-5.42%)	Target met	Sell	pdf post cache	Broker Report Weak advertising growth persists; margins steady Emkay Zee reported another quarter of subpar advertising growth, down another 8% YoY in Q3FY25. Ad revenue has now declined (YoY) in nine of the last ten quarters. pdf Copy Link Share on Share on Share on Share on Alert
	23 Jan 2025	HDFC Bank	Emkay	965.25	2100.00	1664.90 (-42.02%)	Pre-Bonus/ Split	Buy	pdf post cache	Broker Report Slower growth, but nearly stable margins, retail asset quality Emkay HDFC Bank reported a slight miss (of 2%) on PAT, which came in at Rs167bn/1.8% RoA, primarily due to slower credit growth and higher provisions. Deposit growth remains healthy at 16% YoY/2.5% QoQ (up by Rs0.6trn QoQ), but credit growth fell to a new low of 3% YoY as the bank focused on LDR management (down by160bps QoQ to 98%). pdf Copy Link Share on Share on Share on Share on Alert
	23 Jan 2025	Go Digit Insurance	Emkay Target	343.70	250.00	327.35 (4.99%)	27.26	Sell	pdf post cache	Broker Report Good Quarter; doubt persists over sustainable and profitable growth; reiterate SELL Emkay Go Digit reported a better set of numbers in Q3FY25 than our estimates, on account of higher inward reinsurance business growth and sharp improvement in Group Health (including PA) underwriting. pdf Copy Link Share on Share on Share on Share on Alert
	23 Jan 2025	Persistent Systems	Emkay Target	4955.40	5300.00	6287.70 (-21.19%)	Target met	Sell	pdf post cache	Broker Report Broad-based growth; upgrade to REDUCE on recent correction Emkay Q3FY25 operating performance was a tad better than our estimate. Revenue growth of 4.6% QoQ CC was in-line, while EBITM of 14.9% was slightly ahead of our estimate. Unlike in previous few quarters, growth was broad-based across verticals/geographies pdf Copy Link Share on Share on Share on Share on Alert
more loading

Emkay Broker Research reports

Latest broker research reports from Emkay buy, sell, hold, neutral recommendations along with share price targets forecast and upside.

Better refining drives profitability beat; outlook steady

Near-term outlook weak; step up in execution is key

Manages headline NPAs with an eye on Universal bank license

Core US business weakness coming to the fore

Stellar revenue growth; another quarter of profit miss

Another quarter of operating performance miss; downgrade to REDUCE

Weak advertising growth persists; margins steady

Slower growth, but nearly stable margins, retail asset quality

Good Quarter; doubt persists over sustainable and profitable growth; reiterate SELL

Broad-based growth; upgrade to REDUCE on recent correction

Advisor Screeners